In 2023, experts decided against adding obesity drugs to the World Health Organisation's essential medicines list.

Viking is developing what might be a game-changing medication in the segment.

Adding to the pressure is that CVS Health has retained coverage of Zepbound's arch rival Wegovy (semaglutide), sold by Novo ...

The U.S. State Department has approved the potential sale of F-16 training and sustainment, along with related equipment, for ...

Health Canada begins a priority review of semaglutide 2.4 mg, a weekly treatment by Novo Nordisk for MASH, a liver disease ...

More than a billion people now have obesity worldwide, according to the WHO, and around 70% of them live in low and ...

Health Secretary Robert F. Kennedy Jr. will testify before the U.S. Senate's health committee on May 14, the panel said on ...

The U.S. Food and Drug Administration has accepted Novo Nordisk's marketing application for an oral version of its ...

On this week’s episode of the Readout LOUD, we review President Trump’s first 100 days, the return of biotech M&A, strong ...

GLP-1 drug prices are falling. That's good news for patients, but perhaps not such good news for pharmaceutical stock ...

Britain's blue-chip index notched its 15th consecutive session of gains - its longest winning streak on record - as investors ...

Alphabet's Google will face a trial in September on antitrust enforcers' proposals to make it sell off part of its ...